Zacks: Brokerages Expect Supernus Pharmaceuticals Inc (SUPN) to Post $0.44 Earnings Per Share

Wall Street brokerages expect Supernus Pharmaceuticals Inc (NASDAQ:SUPN) to announce earnings of $0.44 per share for the current quarter, Zacks reports. Four analysts have made estimates for Supernus Pharmaceuticals’ earnings. The highest EPS estimate is $0.52 and the lowest is $0.31. Supernus Pharmaceuticals reported earnings of $0.49 per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 10.2%. The business is scheduled to report its next quarterly earnings report on Tuesday, May 14th.

According to Zacks, analysts expect that Supernus Pharmaceuticals will report full year earnings of $2.37 per share for the current year, with EPS estimates ranging from $2.15 to $2.70. For the next financial year, analysts forecast that the company will post earnings of $2.94 per share, with EPS estimates ranging from $2.55 to $3.15. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover Supernus Pharmaceuticals.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Tuesday, February 26th. The specialty pharmaceutical company reported $0.48 EPS for the quarter, topping the consensus estimate of $0.29 by $0.19. The business had revenue of $113.50 million during the quarter, compared to the consensus estimate of $105.36 million. Supernus Pharmaceuticals had a net margin of 27.14% and a return on equity of 27.45%. Supernus Pharmaceuticals’s revenue was up 31.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.26 EPS.



SUPN has been the subject of a number of recent analyst reports. Cantor Fitzgerald reaffirmed a “buy” rating and set a $57.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, February 27th. Cowen set a $55.00 price objective on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, November 30th. Mizuho upped their price objective on shares of Supernus Pharmaceuticals from $61.00 to $63.00 and gave the stock a “buy” rating in a research report on Monday, December 17th. B. Riley set a $65.00 price objective on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, March 4th. Finally, Zacks Investment Research upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $44.00 price objective for the company in a research report on Wednesday. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $55.75.

In related news, CFO Gregory S. Patrick sold 20,000 shares of the stock in a transaction on Wednesday, February 27th. The shares were sold at an average price of $41.53, for a total transaction of $830,600.00. Following the transaction, the chief financial officer now directly owns 67,896 shares of the company’s stock, valued at $2,819,720.88. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 6.20% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Meeder Asset Management Inc. lifted its stake in shares of Supernus Pharmaceuticals by 511.1% in the fourth quarter. Meeder Asset Management Inc. now owns 880 shares of the specialty pharmaceutical company’s stock valued at $30,000 after buying an additional 736 shares in the last quarter. Advisor Group Inc. lifted its stake in shares of Supernus Pharmaceuticals by 17.2% in the fourth quarter. Advisor Group Inc. now owns 2,082 shares of the specialty pharmaceutical company’s stock valued at $69,000 after buying an additional 306 shares in the last quarter. Cutler Group LP bought a new position in shares of Supernus Pharmaceuticals in the fourth quarter valued at $89,000. Quantbot Technologies LP bought a new position in shares of Supernus Pharmaceuticals in the third quarter valued at $113,000. Finally, Gryphon Financial Partners LLC lifted its stake in shares of Supernus Pharmaceuticals by 302.5% in the third quarter. Gryphon Financial Partners LLC now owns 4,037 shares of the specialty pharmaceutical company’s stock valued at $204,000 after buying an additional 3,034 shares in the last quarter. 97.89% of the stock is currently owned by institutional investors and hedge funds.

Shares of SUPN stock traded down $0.76 during midday trading on Friday, hitting $37.74. 21,409 shares of the company were exchanged, compared to its average volume of 630,979. The company has a market capitalization of $2.01 billion, a price-to-earnings ratio of 18.41 and a beta of 1.62. The company has a debt-to-equity ratio of 0.73, a quick ratio of 2.90 and a current ratio of 3.06. Supernus Pharmaceuticals has a 52 week low of $30.05 and a 52 week high of $61.25.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.

Featured Story: How to calculate compound interest

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply